Alternate Funding Mechanisms in Rare Dise...
0円
Every rare disease begins with a patient and a question: why isn’t there a treatment? Too often, the answer isn’t scientific, it is financial. The science exists. The will does exist. But the funding pathways don’t. For decades, rare disease research has been caught between two worlds: public gra...
0円
Every rare disease begins with a patient and a question: why isn’t there a treatment? Too often, the answer isn’t scientific, it is financial. The science exists. The will does exist. But the funding pathways don’t. For decades, rare disease research has been caught between two worlds: public gra...
Ten-Finger Discount: When a Nice Letter t...
1,000円
There was a time when you could write a letter to a company, and they would write you back.
Consumer Affairs, they called it. And they had a ton money to burn, an ongoing effort to keep customers happy. As they loved to say in retail in times long gone: "The Customer is always right!"
Mike Knox' ...
1,000円
There was a time when you could write a letter to a company, and they would write you back.
Consumer Affairs, they called it. And they had a ton money to burn, an ongoing effort to keep customers happy. As they loved to say in retail in times long gone: "The Customer is always right!"
Mike Knox' ...
The Queen of Grants 2
2,113円
The Queen of Grants 2: GrantTalk Secrets for the New Era of Grant Writing continues Libby Hikind's mission and continues The Queen of Grants series to help organizations strengthen their programs, expand their opportunities, and understand what truly supports successful funding. Drawing from deca...
2,113円
The Queen of Grants 2: GrantTalk Secrets for the New Era of Grant Writing continues Libby Hikind's mission and continues The Queen of Grants series to help organizations strengthen their programs, expand their opportunities, and understand what truly supports successful funding. Drawing from deca...